Editorial Comment on: Buyer Beware: Evidence‐Based Evaluation of Dietary Supplements for Nephrolithiasis by Koo et al. (J Endourol 2020;34(6):702–707;DOI: 10.1089/end.2019.0828)
Restricted accessResearch articleFirst published online June, 2020
Editorial Comment on: Buyer Beware: Evidence‐Based Evaluation of Dietary Supplements for Nephrolithiasis by Koo et al. (J Endourol 2020;34(6):702–707;DOI: 10.1089/end.2019.0828)
ScalesCDJr., SmithAC, HanleyJM, SaigalCS, Urologic Diseases in America P. Prevalence of kidney stones in the United States. Eur Urol, 2012; 62:160–165.
2.
TrinchieriA, OstiniF, NespoliR, RoveraF, MontanariE, ZanettiG.A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol, 1999; 162:27–30.
3.
SaigalCS, JoyceG, TimilsinaAR, Urologic Diseases in America P. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?. Kidney Int, 2005; 68:1808–1814.
4.
DauwCA, YiY, BierleinMJ, et al.Factors associated with preventive pharmacological therapy adherence among patients with kidney stones. Urology, 2016; 93:45–49.
5.
SternKL, CanvasserN, BorofskyM, et al.Alkalinizing agents: A review of prescription, over‐the‐counter, and medical food supplements. J Endourol, 2020; 34:1–6.
6.
KooK, AroT, MatlagayBR. Buyer beware: Evidence‐based evaluation of dietary supplements for nephrolithiasis. J Endourol, 2020; 34:702–707.
